Daniel Lemaitre - Globus Medical Independent Director
| GMED Stock | USD 83.93 0.20 0.24% |
Director
Mr. Daniel T. Lemaitre is Independent Director of the Company. Mr. Lemaitre most recently served as the President and Chief Executive Officer of Direct Flow Medical. Previously, Mr. Lemaitre served as Chief Executive Officer of White Pine Medical, a venturebacked medical device startup company, from June 2009 until May 2015. Prior to White Pine Medical, Mr. Lemaitre served as the President and Chief Executive Officer of CoreValve, a privatelyheld company focused on percutaneous aortic valve replacement, from April 2008 until its acquisition by Medtronic, Inc., a publiclytraded medical device company, in April 2009. From 2005 until March 2008, Mr. Lemaitre was a Senior Vice President at Medtronic, where he led the companys strategic planning and corporate development. Prior to joining Medtronic, Mr. Lemaitre spent 28 years as an investment analyst in the medical device field. This included 18 years with SG Cowen, where he was a managing director and led the healthcare research team, and six years with Merrill Lynch. Mr. Lemaitre holds a B.A. in Economics from Bethany College and an M.B.A. from Bowling Green State University. Mr. Lemaitre also currently serves as the Chairman of the Board of Directors of Endologix, Inc. . Mr. Lemaitres extensive business, managerial, executive and leadership experience in the medical device industry, including having served as chief executive officer of a medical device company and as senior vice president of one of the worlds leading medical technology companies, as well as his current experience as a director of a publiclytraded medical device company bring to our Board of Directors a meaningful understanding of our business and industry and valuable skills related to strategic planning for a public company. These skills and experience, as well as his financial and accounting skills and expertise, qualify him to serve as one of our directors and as an audit committee financial expert on our Audit Committee. since 2011.
| Age | 66 |
| Tenure | 14 years |
| Address | 2560 General Armistead Avenue, Audubon, PA, United States, 19403 |
| Phone | 610 930 1800 |
| Web | https://www.globusmedical.com |
Globus Medical Management Efficiency
The company has return on total asset (ROA) of 0.0473 % which means that it generated a profit of $0.0473 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0222 %, meaning that it created $0.0222 on every $100 dollars invested by stockholders. Globus Medical's management efficiency ratios could be used to measure how well Globus Medical manages its routine affairs as well as how well it operates its assets and liabilities. As of February 16, 2025, Return On Tangible Assets is expected to decline to 0.05. In addition to that, Return On Capital Employed is expected to decline to 0.03. At present, Globus Medical's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 94.9 M, whereas Return On Tangible Assets are forecasted to decline to 0.05.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Brian Concannon | CONMED | 62 | |
| Marc Stapley | Glaukos Corp | 50 | |
| Gilbert Kliman | Glaukos Corp | 61 | |
| Filippo Passerini | Integer Holdings Corp | 63 | |
| David Bronson | CONMED | 67 | |
| Charles Farkas | CONMED | 68 | |
| Jerry Griffin | Inspire Medical Systems | 76 | |
| Mark Foley | Glaukos Corp | 55 | |
| Stephanie Zhadkevich | iRhythm Technologies | N/A | |
| Martha Aronson | CONMED | 53 | |
| Shawn McCormick | Inspire Medical Systems | 56 | |
| Dana Mead | Inspire Medical Systems | 61 | |
| Pamela Bailey | Integer Holdings Corp | 72 | |
| John Workman | CONMED | 69 | |
| Martin Maxwell | Integer Holdings Corp | 62 | |
| Jean Hobby | Integer Holdings Corp | 60 | |
| Sheila Antrum | Integer Holdings Corp | 62 | |
| Susan Siegel | Nevro Corp | 60 | |
| Shelley Broader | Inspire Medical Systems | 56 | |
| Brad Vale | Nevro Corp | 67 | |
| Donald Spence | Integer Holdings Corp | 67 | |
Management Performance
| Return On Equity | 0.0222 | ||||
| Return On Asset | 0.0473 |
Globus Medical Leadership Team
Elected by the shareholders, the Globus Medical's board of directors comprises two types of representatives: Globus Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Globus. The board's role is to monitor Globus Medical's management team and ensure that shareholders' interests are well served. Globus Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Globus Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steve Zarrilli, Independent Director | ||
| David Paul, Co-Founder, Chairman, CEO, Chairman of Compensation Committee and Chairman of Nominating and Corporate Governance Committee | ||
| Mike Reeder, Ex Officer | ||
| Ann Rhoads, Independent Director | ||
| Robert Douglas, Independent Director | ||
| Steven Payne, VP Controller | ||
| Kelly Esq, Executive Counsel | ||
| Kelly Huller, Senior Vice President General Counsel, Corporate Secretary | ||
| Stephen Zarrilli, Independent Director | ||
| James Tobin, Independent Director | ||
| Brian Kearns, Senior Relations | ||
| Brett Murphy, Group President of Commercial Operations | ||
| Richard Holifield, Ex Officer | ||
| Daniel Lemaitre, Independent Director | ||
| John Dowling, Ex Officer | ||
| Keith Pfeil, Chief Financial Officer, Senior Vice President | ||
| David Demski, Group President of Emerging Technologies, Director and Member of Nominating and Corporate Governance Committee | ||
| Daniel Scavilla, Executive Vice President, Chief Commercial Officer and President - Trauma | ||
| David Davidar, Co-Founder, Sr. VP of Operations and Director |
Globus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Globus Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0222 | ||||
| Return On Asset | 0.0473 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 11.27 B | ||||
| Shares Outstanding | 113.74 M | ||||
| Shares Owned By Insiders | 1.36 % | ||||
| Shares Owned By Institutions | 98.62 % | ||||
| Number Of Shares Shorted | 2.18 M | ||||
| Price To Earning | 73.16 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Globus Medical is a strong investment it is important to analyze Globus Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Globus Medical's future performance. For an informed investment choice regarding Globus Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Globus Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Globus Stock refer to our How to Trade Globus Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Globus Medical. If investors know Globus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Globus Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 42.231 | Earnings Share 0.62 | Revenue Per Share | Quarterly Revenue Growth 0.631 | Return On Assets |
The market value of Globus Medical is measured differently than its book value, which is the value of Globus that is recorded on the company's balance sheet. Investors also form their own opinion of Globus Medical's value that differs from its market value or its book value, called intrinsic value, which is Globus Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Globus Medical's market value can be influenced by many factors that don't directly affect Globus Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Globus Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Globus Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Globus Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.